Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,094
  • Shares Outstanding, K 62,264
  • Annual Sales, $ 16,150 K
  • Annual Income, $ -77,330 K
  • EBIT $ -86 M
  • EBITDA $ -89 M
  • 60-Month Beta 1.36
  • Price/Sales 4.92
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 222.77% (+27.13%)
  • Historical Volatility 224.53%
  • IV Percentile 34%
  • IV Rank 21.22%
  • IV High 889.90% on 03/17/25
  • IV Low 43.04% on 02/12/25
  • Expected Move (DTE 24) 1.1985 (109.95%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 260
  • Volume Avg (30-Day) 1,458
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 11,563
  • Open Int (30-Day) 15,859
  • Expected Range 0.0000 to 2.2885

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.39
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -9.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +3.81%
on 12/23/25
5.5500 -80.36%
on 11/26/25
-3.7100 (-77.29%)
since 11/21/25
3-Month
1.0500 +3.81%
on 12/23/25
5.5500 -80.36%
on 11/26/25
-1.1000 (-50.23%)
since 09/23/25
52-Week
0.8332 +30.82%
on 04/07/25
5.5500 -80.36%
on 11/26/25
-0.5800 (-34.73%)
since 12/23/24

Most Recent Stories

More News
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

-  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology to Participate in September Investor and Industry Conferences

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

–  Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data...

PYXS : 1.0900 (-8.40%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PYXS : 1.0900 (-8.40%)
This Natural Killer Treatment Could Help Transform How Cancer is Treated

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic...

PYXS : 1.0900 (-8.40%)
IOVA : 2.82 (+1.44%)
BTAI : 1.7300 (-0.57%)
GTBP : 0.8050 (+4.02%)
FATE : 0.9768 (-6.97%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.4192
2nd Resistance Point 1.3373
1st Resistance Point 1.2137
Last Price 1.0900
1st Support Level 1.0082
2nd Support Level 0.9263
3rd Support Level 0.8027

See More

52-Week High 5.5500
Fibonacci 61.8% 3.7482
Fibonacci 50% 3.1916
Fibonacci 38.2% 2.6350
Last Price 1.0900
52-Week Low 0.8332

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar